Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 28, 2010

Aeterna Zentaris Taps Almac to Develop Companion Diagnostic for Its Cancer Drug

  • Aeterna Zentaris and Almac are teaming up to develop a companion diagnostic for the former’s anticancer agent AEZS-108. The therapy is a doxorubicin luteinizing hormone-releasing hormone targeted conjugate compound, and selection for treatment is based on LHRH receptor expression.

    In humans LHRH receptors are expressed in ovarian, endometrial, breast, bladder, prostate, and pancreatic tumors. AEZS-108 is in Phase II trials for advanced LHRH receptor-positive ovarian and endometrial cancer. An IND is in place for the treatment of bladder cancer. Currently, patients are chosen based on immunohistochemistry measurements.

    Positive results in ovarian cancer for AEZS-108 were disclosed at this year’s ASCO meeting, while data in endometrial cancer is expected by year-end. The compound has been granted orphan-drug designation by the FDA and has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products of the EMEA.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »